Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
AbstractAngiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities. Compared with the drugs in the clinic, these agents display interesting characteristics, including diverse sources, unique chemical structures, special modes of action, and distinct activity and toxicity profiles. This review will first provide an overview of the current marine-derived angiogenesis inhibitors based on their primary targets and/or mechanisms of action. Then, the marine-derived antiangiogenic protein kinase inhibitors will be focused on. And finally, the clinical trials of the marine-derived antiangiogenic agents will be discussed, with special emphasis on their application potentials, problems and possible coping strategies in their future development as anticancer drugs. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Wang, Y.-Q.; Miao, Z.-H. Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. Mar. Drugs 2013, 11, 903-933.
Wang Y-Q, Miao Z-H. Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. Marine Drugs. 2013; 11(3):903-933.Chicago/Turabian Style
Wang, Ying-Qing; Miao, Ze-Hong. 2013. "Marine-Derived Angiogenesis Inhibitors for Cancer Therapy." Mar. Drugs 11, no. 3: 903-933.